Wungki Park, Assistant Attending at Memorial Sloan Kettering Cancer Center and Assistant Professor of Medicine at Weill Cornell Medicine shared a post on LinkedIn:
“Thank you ESMO – European Society for Medical Oncology for your kind highlight of this POLAR study in Nature.
‘These results provide a rationale for ongoing randomised studies (e.g., SWOG S2001) and future precision immunotherapy trials that integrate DDR status, neoantigen quality and TME remodelling to improve outcomes in patients with pancreatic cancer.’
Huge multidimensional temporospatial datasets for deeper knowledge and science for our patients!”
Other articles about ESMO on OncoDaily.
